96 related articles for article (PubMed ID: 8069558)
1. Progress review: intrathecal and intratumoral injection of radiolabelled monoclonal antibodies (MoAbs) for the treatment of central nervous system (CNS) malignancies.
Hopkins K; Kemshead JT
J Drug Target; 1993; 1(3):175-83. PubMed ID: 8069558
[TBL] [Abstract][Full Text] [Related]
2. Immunotoxins for central nervous system malignancy.
Youle RJ
Semin Cancer Biol; 1996 Apr; 7(2):65-70. PubMed ID: 8740561
[TBL] [Abstract][Full Text] [Related]
3. Treatment of recurrent and cystic malignant gliomas by a single intracavity injection of 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry.
Papanastassiou V; Pizer BL; Coakham HB; Bullimore J; Zananiri T; Kemshead JT
Br J Cancer; 1993 Jan; 67(1):144-51. PubMed ID: 8427774
[TBL] [Abstract][Full Text] [Related]
4. [Immunotherapy and cancer: the role of monoclonal antibodies].
Dumontet C
J Chir (Paris); 1989 Dec; 126(12):682-6. PubMed ID: 2695534
[TBL] [Abstract][Full Text] [Related]
5. Experimental therapy of human breast tumors with 131I-labeled monoclonal antibodies prepared against the human milk fat globule.
Ceriani RL; Blank EW
Cancer Res; 1988 Aug; 48(16):4664-72. PubMed ID: 3396015
[TBL] [Abstract][Full Text] [Related]
6. Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.
Bodey B; Siegel SE; Kaiser HE
Anticancer Res; 1996; 16(2):661-74. PubMed ID: 8687112
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal antibodies in the treatment of hematopoietic malignancies.
Houghton A; Scheinberg D
Semin Hematol; 1988 Jul; 25(3 Suppl 3):23-9. PubMed ID: 3051406
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal 131I- and 90Y-labelled monoclonal antibodies for ovarian cancer: pharmacokinetics and normal tissue dosimetry.
Stewart JS; Hird V; Snook D; Sullivan M; Myers MJ; Epenetos AA
Int J Cancer Suppl; 1988; 3():71-6. PubMed ID: 3209303
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and dose estimates following intrathecal administration of 131I-monoclonal antibodies for the treatment of central nervous system malignancies.
Papanastassiou V; Pizer BL; Chandler CL; Zananiri TF; Kemshead JT; Hopkins KI
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):541-52. PubMed ID: 7852118
[TBL] [Abstract][Full Text] [Related]
10. Anticancer therapies and CNS relapse: overcoming blood-brain and blood-cerebrospinal fluid barrier impermeability.
Chamberlain MC
Expert Rev Neurother; 2010 Apr; 10(4):547-61. PubMed ID: 20367207
[TBL] [Abstract][Full Text] [Related]
11. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options.
Ferreri AJ; Assanelli A; Crocchiolo R; Ciceri F
Hematol Oncol; 2009 Jun; 27(2):61-70. PubMed ID: 19247977
[TBL] [Abstract][Full Text] [Related]
13. Primary CNS lymphoma.
Gerstner E; Batchelor T
Expert Rev Anticancer Ther; 2007 May; 7(5):689-700. PubMed ID: 17492932
[TBL] [Abstract][Full Text] [Related]
14. Germ cell tumours of the central nervous system in children-controversies in radiotherapy.
Borg M
Med Pediatr Oncol; 2003 Jun; 40(6):367-74. PubMed ID: 12692804
[TBL] [Abstract][Full Text] [Related]
15. [Treatment results and the prognosis in patients with localization of non-Hodgkins-lymphoma in the central nervous system].
Paulus JA; Bos GM; Löwenberg B; Van Den Bent MJ
Ned Tijdschr Geneeskd; 1998 Oct; 142(40):2196-200. PubMed ID: 9864481
[TBL] [Abstract][Full Text] [Related]
16. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects.
Gökbuget N; Hoelzer D
Ann Hematol; 2004 Apr; 83(4):201-5. PubMed ID: 14648023
[TBL] [Abstract][Full Text] [Related]
17. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
[TBL] [Abstract][Full Text] [Related]
18. Direct injection of 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose.
Hopkins K; Chandler C; Eatough J; Moss T; Kemshead JT
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(4):835-44. PubMed ID: 9531368
[TBL] [Abstract][Full Text] [Related]
19. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
[TBL] [Abstract][Full Text] [Related]
20. Radiotherapy vs intrathecal chemotherapy for CNS prophylaxis in childhood ALL.
Steinherz PG
Oncology (Williston Park); 1989 Sep; 3(9):47-53; discussion 58-60. PubMed ID: 2701698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
